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Key words: Osteoarthritis, Genetic, Collagen.Our goals for osteoarthritis (OH) are straightforward: we
need to define the causes of the disease and/or ‘the
cascade of events’ that produce the degeneration of joint
cartilage. From there we need to move on to methods of
preventing or curing the disease.
As is well recognized, there are multiple causes for the
degeneration of joint cartilage seen in OA. One of the
hypotheses that we have pursued is that genetic mutations
produce OA in a subset of patients with early onset forms of
the disease. Another hypothesis we have pursued is that
genetically caused OA may be the easiest target for both
diagnosis and therapies for the disease.
Accordingly, we began several years ago to use the
candidate gene strategy to search for mutations in the gene
for type II procollagen (COL2A1) in patients with early
onset OA. In a proband referred to us by Dr Roland
Moskowitz and his colleagues at Case Western Reserve,
we located a single-base substitution that converted a
codon for arginine to a codon for cysteine at the a 1-519
position in the triple helix of the protein.1 The detection of
the cysteine substitution suggested that the mutation was a
disease-causing change because cysteine is not found in
the interior of the triple helix of any fibrillar collagen.
However, in common diseases such as OA it is frequently
very difficult to be certain that a change seen in a gene
does in fact cause the disease. Fortunately, Dr Moskowitz
and his colleagues were able to provide us with data on the
patient’s family, and it was possible to show that the
mutation was co-inherited with the disease in a statistically
convincing manner (lod score of greater than 3.0). Eyre et
al.2 demonstrated that type II collagen extracted from the
patient’s cartilage formed abnormal disulfide bonds. Sub-
sequently, we were able to demonstrate that the mutation
generates abnormal fibrils in a purified system for assembly
of type II collagen fibrils.3
Examination of the fibrils by atomic force microscopy
demonstrated that the mutated protein has the unusual
effect of increasing the depth of the gap region in collagen
fibrils (E. Adachi, O. Katsuma, S. Yamashina, D. J. Prockop,
and A. Fertala, submitted for publication). More recently, we
developed a line of transgenic mice expressing the mutated
gene. Our preliminary observations on the transgenic mice
suggest that they develop cartilage changes that resemble
OA (S.-W. Li, M. Arita, L. Ala-Kokko, D. J. Prockop, in
preparation). Therefore, we now have thoroughly convinc-
ing data that the mutation in this family caused the clinical
syndrome of early onset OA associated with evidence of a364mild chondrodysplasia. Over the past several years, four
other patients and families with similar findings have also
been shown to have the same cysteine for arginine substi-
tution at a 1-519.4 Three of the patients and families may
have been related through an early Icelandic founder.
Our initial survey of some 50 patients with OA indicated
that only about 2% of such patients have mutations in
the gene for type II procollagen.5 Therefore, Dr Leena
Ala-Kokko, in our Center for Gene Therapy, has developed
a strategy in which DNA from such patients is examined for
the presence of mutations in six different collagen genes
that are found in cartilage. This strategy is an ambitious one
because collagen genes are large and have complex
structures that include 50 or more exons. Therefore, com-
plete analysis of such genes for the presence of mutations
still presents serious technical problems. Our work has
been aided by two developments. One development is a
procedure referred to as ‘conformation sensitive gel elec-
trophoresis’ (CSGE) developed by Dr Arupa Ganguly in our
laboratory.6 CSGE is a modification of previously proposed
techniques for detection of single-base changes in PCR
products by gel electrophoresis under appropriate con-
ditions. We have extensively tested CSGE over the last
several years and convinced ourselves that it detects 90%
or more of single-base changes in PCR products.7
The technique is simple, rapid, and greatly reduces the
amount of DNA sequencing we need to perform in order to
analyze genes for mutations. The second development are
the impressive achievements of Dr Leena Ala-Kokko and
her graduate students in our Center and at the University of
Oulu in defining the structures of a series of large and
complex human collagen genes (see 8). With these devel-
opments, we are perfecting protocols whereby we can
analyze DNA from patients first for mutations in the
COL2A1 gene, then in the three genes for type IX collagen
(COL9A1, COL9A2, and COL9A3), and then in the two
genes for type Xl collagen (COL11A1, and COL11A2). If no
mutations are found, the same samples can be screened
for mutations in other genes expressed in cartilage such as
COMP, link protein and aggrecan.
The efforts in pursuing this expanded candidate gene
strategy in OA are still incomplete. Our present estimate is
that mutations in the six collagen genes will be found in
about 5% of patients with early onset OA. One of our
conclusions is that heritable OA is one end of a spectrum of
cartilage disorders that range from severe chondro-
dysplasias that can prove lethal in utero to much milder
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wear and tear in the joints.9 In addition, we are convinced
that a number of patients who present with early onset OA
in adulthood probably had signs and symptoms of a mild
chondrodysplasia in childhood, but those signs and
symptoms frequently escape detection. Another conclusion
is that the signs and symptoms seen in a patient are in
some instances highly informative as to which gene con-
tains a causative mutation, but in many instances, the
same clinical syndrome can be produced by mutations in
very different genes. For example, Dr Ala-Kokko and
her associates have recently demonstrated that an RNA
splicing mutation in one of the genes for type Xl collagen
(COL11A2) causes what appears to be a relatively com-
mon form of early onset OA (S. Annunen et al., submitted
for publication). As another example, a mutation in one of
the three genes for type IX collagen (COL9A1) in two
families and several unrelated patients causes marked
degeneration intervertebral discs (S. Annunen et al.,
submitted for publication).
Even though our knowledge about the causes of OA is
still incomplete, preliminary attempts are being made in a
number of laboratories to develop cell and gene therapies
for the disease. One approach has been to isolate samples
of normal cartilage from a patient, expand chondrocytes in
the laboratory, and then use the expanded chondrocytes to
replate the degenerated joint surface. One commercial
concern is pursuing this strategy at the present time. A
second approach has been to use viral vectors with which
to introduce potentially therapeutic genes and proteins into
joints. The appeal of this strategy is that the modified virus
can probably be injected directly into joint spaces and
thereby minimize any systemic effects. The use of viruses
for gene therapy has proven to be more complex than
initially assumed, but a large number of talented investi-
gators are pursuing this strategy and it is likely to be fruitful
in the near future. A third strategy has been to use as
vectors for cell and gene therapy a subset of cells from
bone marrow that have been referred to as mesenchymal
stem cells or marrow stromal cells (MSCs). MSCs have
attracted attention since the work of Friedenstein in the
1970s10 in which he demonstrated that bone marrow
contains a subset of stem-like cells that are distinct from
stem cells for hematopoietic precursors and that serve as
precursors of non-hematopoietic cells such as osteoblasts,
chondrocytes and adipocytes. Friedenstein’s work has now
been amply confirmed and extended by a large number of
investigators including Piersma in the Netherlands, Owen
at Oxford and Caplan at Case Western Reserve [for review,
see 11].
In our laboratory we carried out a series of experiments
in which MSCs were isolated from transgenic mice contain-
ing a marker collagen gene and infused systemically into
X-ray irradiated isogenic mice.12 The results demonstrated
that the donor cells were difficult to detect at one week, but
they appeared in a variety of non-hematopoietic tissues at
one month and five months. They accounted for between 2
and 20% of the cells in bone, cartilage, lung and several
other tissues. In part based on our results in mice, Drs Ed
Horwitz and Malcolm Brenner at St. Jude Children’s
Research Hospital in Memphis initiated a clinical trial
in patients with severe osteogenesis imperfecta (OI).13
The trial was based on the assumption that whole bone
marrow may contain enough MSCs to engraft in bone
and replace osteoblasts containing a mutated collagen
gene with osteoblasts containing a normal gene. Three
patients with severe OI who were marrow ablated andreceived bone marrow transplants from matched siblings
have been evaluated six months after therapy.14 All three
patients have shown improvement in fracture rate, growth,
bone histomorphometry and total body mineral as assayed
by DEXA. However, osteoblasts from bone spicules
obtained from two of the probands indicated that only 1 to
2% of the cells were of donor origin. Therefore, it is not
clear whether the clinical improvement in the patients can
be explained by infusion of MSCs or by some unexpected
consequence of marrow ablation and bone marrow trans-
plantation.
In more recent experiments,15 we have asked the ques-
tion of whether human MSCs will engraft and migrate like
neural stem cells after infusion into the brains of rats. The
background of the experiment was that a large body of data
developed over the last five years or so has shown that the
brain normally develops from stem-like cells that line the
ventricles and then move along known pathways through
the layers of the brain. As they reach a given layer, they
acquire the phenotype of the cells in that layer. The process
is prominent during early development of the brain, but it
continues at a slower rate in adults. Our thinking for the
experiment was also guided by the therapy for Parkinson’s
disease developed by a group of Swedish neurosurgeons
in which cells isolated from the brains of human abortuses
were injected into the basal ganglia of patients [see 15].
Over 80 patients with Parkinson’s disease have received
the treatment, and a number have shown objective signs
for improvement [see 16]. The application of the treatment
is limited, however, by the difficulty in obtaining the neces-
sary human fetal cells. In our experiments, one surprise
was that the human MSCs did not induce any inflammatory
or immune reactions after injection into the brains of rats.
Another surprise was that the cells did not aggregate and
induce gliosis as is seen with infusion of fibroblasts and a
number of other cell types. Instead, the cells migrated
along known pathways for the migration of stem cells and
integrated into multiple layers of the brain. Assay of sec-
tions of the brain indicated that at least 15% of the human
cells had survived for 6 months.
These and other observations by other investigators
suggest that MSCs are attractive vectors for cell and gene
therapy in a variety of diseases. They are relatively easy to
isolate from a patient and engineer in culture. Also, after
systemic infusion, they home to many tissues and then
apparently they acquire the phenotypes of the cells nor-
mally found in the same tissues. For example, they become
chondrocytes in cartilage. The implications for therapy of
OA is that it may be possible to isolate MSCs from a
patient, engineer the cells so they express a therapeutic
protein such as IL-Ra, IL4, or IL1O, and then use the cells
for therapy of the same patient. The expression of the
potentially therapeutic protein can be engineered so that it
is driven by cartilage specific protein. The most likely
application would be by intra-articular injection of the gene-
engineered MSCs. However, it is possible that systemic
infusion of the same cells may be followed by a sufficient
number of the cells homing to cartilage and then express-
ing the therapeutic protein under the influence of the
cartilage-specific promoter.References
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